(AOF) – Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, announces the appointment of Mathieu Charvériat as Chairman of the Board of Directors following the resignation of Franck Mouthon, from March 31, 2024. As part of this new organization, Franck Mouthon, who takes on new responsibilities as executive director of the Health Research Program Agency, will continue his mandate as administrator within Theranexus.
Mathieu Charvériat will continue to serve as Managing Director in addition to Chairmanship of the Board of Directors.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
